Reuters logo
2 个月前
BRIEF-Soleno Therapeutics announces completion of FDA meeting for DCCR in Prader-Willi syndrome
2017年7月5日 / 中午12点16分 / 2 个月前

BRIEF-Soleno Therapeutics announces completion of FDA meeting for DCCR in Prader-Willi syndrome

July 5 (Reuters) - Soleno Therapeutics Inc

* Soleno Therapeutics announces successful completion of FDA meeting for DCCR in Prader-Willi syndrome

* Soleno Therapeutics Inc says positive guidance received on key elements of phase III program

* Soleno Therapeutics Inc says expects to initiate pivotal phase III clinical trial by year-end 2017

* Soleno Therapeutics -FDA expressed support for change in hyperphagia score, without a change in weight, compared to placebo as primary endpoint for study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below